Title:
BENZOAZEPINE COMPOUND-CONTAINING PHARMACEUTICAL COMPOSITION
Document Type and Number:
WIPO Patent Application WO/2020/196816
Kind Code:
A1
Abstract:
A means for reducing side effects of tolvaptan is provided. Specifically, the means provides a pharmaceutical composition comprising a compound represented by Formula (1) or a metal salt thereof, wherein the pharmaceutical composition is used such that the compound represented by Formula (1) or a metal salt thereof is transvascularly administered in an amount of 4 to 20 mg over a period of 10 minutes or more.
Inventors:
CHIHARA TOMIHIKO (JP)
UNO SHINGO (JP)
UNO SHINGO (JP)
Application Number:
PCT/JP2020/013935
Publication Date:
October 01, 2020
Filing Date:
March 27, 2020
Export Citation:
Assignee:
OTSUKA PHARMA CO LTD (JP)
International Classes:
A61K31/675; A61P1/16; A61P9/04; A61P13/12; A61P17/04
Domestic Patent References:
| WO2007074915A1 | 2007-07-05 | |||
| WO2015056805A1 | 2015-04-23 | |||
| WO2007074915A1 | 2007-07-05 |
Foreign References:
| JP2015134837A | 2015-07-27 |
Other References:
SATO N N. ET AL: "P278 Pharmacokinetics, pharmacodynamics and efficacy of OPC-61815, prodrug of tolvaptan for intravenous administration, in patients with congestive heart failure", PHARMACOLOGY AND PHARMACOTHERAPY - POSTER PRESENTATION 31, 13 January 2020 (2020-01-13), pages 1, XP055701874, Retrieved from the Internet [retrieved on 20200605]
Attorney, Agent or Firm:
SAEGUSA & PARTNERS (JP)
Download PDF:
Previous Patent: SYSTEM, METHOD, AND PROGRAM FOR PATIENTS WITH ERECTILE DYSFUNCTION
Next Patent: SPECTRAL ANALYSIS CHIP
Next Patent: SPECTRAL ANALYSIS CHIP